Jones Wallace, Griffiths Kelly, Barata Pedro C, Paller Channing J
Department of Internal Medicine, Tulane University School of Medicine, New Orleans, LA 70112, USA.
Johns Hopkins University, Sidney Kimmel Comprehensive Cancer Center, Baltimore, MD 21231 USA.
Cancers (Basel). 2020 May 26;12(6):1367. doi: 10.3390/cancers12061367.
Prostate-specific membrane antigen (PSMA) has been the subject of extensive investigation in the past two decades as a promising molecular target for prostate cancer (PCa). Its appealing molecular features have enabled the development of a novel diagnostic and therapeutic-thus "theranostic"-approach to PCa. There is now substantial evidence of the high sensitivity of PSMA-targeted imaging for PCa lesions and growing evidence of the therapeutic efficacy of PSMA radioligand therapy for metastatic castration-resistant prostate cancer. This article presents a broad overview of the current status of PSMA theranostics, including current evidence, potential clinical impact, and active areas of research.
在过去二十年中，前列腺特异性膜抗原（PSMA）作为前列腺癌（PCa）一个有前景的分子靶点，一直是广泛研究的对象。其吸引人的分子特性促成了一种针对PCa的新型诊断与治疗——即“治疗诊断”——方法的发展。目前有大量证据表明PSMA靶向成像对PCa病灶具有高敏感性，并且越来越多的证据显示PSMA放射性配体疗法对转移性去势抵抗性前列腺癌具有治疗效果。本文全面概述了PSMA治疗诊断学的现状，包括现有证据、潜在临床影响和活跃的研究领域。
